Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma

Hodgkin lymphoma (HL) represents ~11% of all lymphoma cases. This disease occurs in young adults, but also affects people over 55 years of age. Despite the fact that >80% of all newly diagnosed patients under 60 will achieve a sustained complete response (CR), 5%–10% of HL patients are refractory...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: Garcia-Recio, Marta, Martinez-Serra, Jordi, Mestre, Francesc, Bento, Leyre, Gines, Jordi, Ramos, Rafael, Daumal, Jaime, López, Paloma, Sampol, Antonia, Gutierrez, Antonio
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2018
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6188182/
https://ncbi.nlm.nih.gov/pubmed/30349293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S175016
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky